Stem Cell Transplantation
Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.
Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.
Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).
Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.
Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.
Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical TransplantationApril 25, 2016
Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.
Current presence of pain was associated with both greater depression and fatigue in survivors of hematopoietic stem cell transplantation (HSCT).
Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.
For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.
For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.
Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)November 25, 2015
More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.
A sleep deficit of just 4 hours affects the ability of blood and immune-system stem cells to migrate to the proper spots in the bone marrow of recipient mice and churn out the cell types necessary to reconstitute a damaged immune system by as much as 50%.
High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With AmyloidosisOctober 27, 2015
Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.
Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.
Greatly improved outcomes have been observed in using stem cell transplantation to treat patients with juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer.
An experimental new treatment approach could buy patients with a rare and dangerous leukemia type the time to obtain a stem cell transplant.
Younger, unrelated donors with high T cell counts make better matches for patients undergoing stem cell transplantJune 29, 2015
Measuring the T lymphocyte count in stem cell transplant donors can improve matchmaking for patients in need of an allogeneic stem cell transplant.
Lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival, according to findings from a phase 2 clinical trial.
The stress of caregivers of patients receiving stem cell transplantation can be successfully reduced by an intervention, according to a randomized controlled trial.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.
Study shows need for psychosocial support for patients undergoing hematopoietic stem cell transplantDecember 25, 2014
According to a recent study, patients undergoing hematopoietic stem cell transplantation (HCT) reported a steep problems and substantially worsening depression during hospitalization.
A recent study shows that, in the case of stem cell transplantation in a child, parents feel increased distress at the time of the procedure, but eventually recover.
Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.
Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.
Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.
Growing cord blood stem cells in a laboratory before transplanting them into patients with leukemia, lymphoma, and other blood cancers significantly improves survival, according to a new study.
A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process. The authors called this peer support process "expressive helping."
- Beta-blockers May Improve Survival in Multiple Myeloma
- Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax
- Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma
- LIVESTRONG Exercise Program Improves QoL in Cancer Survivors
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Timing Chemotherapy Administration to Circadian Rhythm Improves Drug Effectiveness
- New Therapy Blocks Breast Cancer Cells From Entering and Hiding in Bone Marrow to Form Latent Metastases
- Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC
- Adding Onartuzumab to Chemo Not Effective for HER2-, MET+ Gastroesophageal Adenocarcinoma
- Rasburicase More Effective Than Allopurinol for Tumor Lysis Syndrome
- Mental Health Disorder Linked to Poorer Survival in NSCLC
- Perindopril, Bisoprolol Not Effective for Preventing Trastuzumab-mediated Left Ventricular Remodeling
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|